NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
»22/03/2010 [Industry news]
Matrix, PharmaVentures sign MoU

Matrix Corporate Capital and PharmaVentures announced the signing of a Memorandum of Understanding covering strategic transactions in the biotech, pharmaceutical and med tech sectors.

 
Matrix Corporate Capital and PharmaVentures announced the signing of a Memorandum of Understanding covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe\'s dedicated healthcare investors. The MoU joins two firms with synergistic transactional capabilities in the healthcare life sciences space. Fintan Walton, Chief Executive of PharmaVentures said \"For our clients our alliance with Matrix will create one of Europe\'s strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement.\" Malcolm Le May, Chief Executive of Matrix Corporate Capital said, \"We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures\' help, will allow us to create innovative transactions around these assets.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.